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Department of Pharmaceutical and Biological Chemistry, Centre for Pharmacognosy and Phytotherapy, University College
London School of Pharmacy, London, UK
It is becoming increasingly evident that patients with diabetes do not rely only on
prescription drugs for their disease management. The use of herbal medicines is one of
the self-management practices adopted by these patients, often without the knowledge
of their healthcare practitioners. This study assessed the potential for pharmacokinetic
herb-drug interactions (HDIs) amongst Nigerian adult diabetic patients. This was done
through a literature analysis of the pharmacokinetic profile of their herbal medicines and
prescription drugs, based on information obtained from 112 patients with type-2 diabetes
attending two secondary health care facilities in Nigeria. Fifty percent of the informants
used herbal medicines alongside their prescription drugs. Worryingly, 60% of the patients
taking herbal medicines did not know their identity, thus increasing the risk of unidentified
HDIs. By comparing the pharmacokinetic profile of eight identified herbs taken by the
patients for the management of diabetes against those of the prescription drugs, several
scenarios of potential HDIs were identified and their clinical relevance is discussed. The
lack of clinical predictors points toward cultural factors as the influence for herb use,
making it more difficult to identify these patients and in turn monitor potential HDIs.
In identifying these possible interactions, we have highlighted the need for healthcare
professionals to promote a proactive monitoring of patients’ use of herbal medicines.
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INTRODUCTION
Herbal medicines are becoming an increasing component ofWestern pharmacotherapymostly due
to the perception that “natural” means “safe” (Brantley et al., 2014). As a result, a large number of
patients with diabetes use them alongside their prescription drugs in disease management (Argáez-
López et al., 2003; Kumar et al., 2006; Hasan et al., 2009); with evidence suggesting a higher use
amongst those with more severe diabetic conditions (Nahin et al., 2012). One reason for this might
be because of the difficulty in attaining adequate glycaemic control in type-2 diabetic patients
despite existing pharmacotherapy, due to the steady decline in beta cell function (Robertson et al.,
2004). Poor glycaemic control increases the risk of diabetic related complications ensuing in more
complex treatment plans which the patients have to deal with for a long time. This characteristic
Abbreviations: ALT, Alanine transaminase; AST, Aspartate transaminase; CYP, Cytochrome P450; GSH, Glutathione; GST,
Glutathione-S-transferases; HDI, Herb-drug interactions; P-gp, P-glycoprotein.
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of the disease lends itself as a condition whose patients are
likely to seek out alternative forms of treatment (Chang et al.,
2007). Unfortunately, this high prevalence is accompanied by
poor communication between patients and clinicians. In the US
for instance, patients with diabetes were identified as the least
likely to inform healthcare practitioners of their use of herbal
medicines (Saydah and Eberhardt, 2006).
With the use of herbal medicine becoming more widespread,
a lot of focus has been given to evaluating them for possible
herb-drug interactions (HDIs), particularly pharmacokinetic
interactions since pharmacodynamic interactions are often easier
to identify and monitor. Efforts have also been made to collate
existing information about herbal medicines as a guide to
healthcare practitioners, and as ameans of forestalling potentially
clinically relevant HDIs (Ulbricht et al., 2008; Williamson et al.,
2013). These resources are however lacking in information
about medicinal plants used in African countries, despite its
proportionately high frequency of use.
The implications of clinically relevant HDIs can have
far-reaching effects for most African populations, such as
Nigeria, with an inadequate healthcare system (Anyika, 2014).
By anticipating potential toxicities or possible herb-drug
interactions, clinically relevant HDIs with significant risks can
be avoided. To address this issue, a fieldwork study to identify
the herbal medicines used by diabetic patients in Nigeria in their
disease management was carried out. The objective of the study
was to assess the potential for pharmacokinetic HDIs amongst
this “at risk” group based on available information about herbal
medicines and the pharmacokinetic profile of the prescribed
drugs used by the patients.
RESEARCH DESIGN AND METHODS
Place of Study and Data Collection
A fieldwork study was conducted in August and September
2012 in the Pharmacy departments of two secondary health
care facilities—the General hospital in Lagos Island and
Central hospital in Benin City—two urban cities in the
southern part of Nigeria. The study-including the proposed
questionnaire to be administered—was approved by the ethics
committee of UCL (Ethics Application 4124/001); and prior
consent was also obtained from the ethics committee of both
hospitals.
During the study period, every prescription that was identified
as having one or more oral hypoglycaemic drugs during the
“prescription assessment stage” was assigned to the interviewer
for drug dispensing and counseling and possible inclusion of
the patient in the study. Each patient was thereafter given a
brief description of the study. However, only patients who gave
their verbal consent to be asked additional questions relating
to their use of herbal medicines, based on a semi-structured
questionnaire were included. These questions were asked while
drugs were being dispensed andmedication counseling was given
to the patients afterwards.
Information obtained from the questionnaire include
demographic background of respondents including age and sex,
information on the identity of the herbs and prescription drugs
used (where available) either for diabetes or other co-morbidities
as well as the monthly cost of prescription. Herbal medicines
as described in this study include the following: supplements
containing extracts of medicinal plants, un-standardized herbal
preparations from herbalists, herbal preparations made by
the patients themselves using plant parts purchased in herbal
markets or collected from their own gardens.
No samples of herbal medicines were collected as part of
the study. The identity of the herbal medicines used, were
provided by the patients either as local names or its common
name in English. Various literature sources were consulted
to determine the botanical names of plants from their given
local names. Verification of their local names were done by
Mr. Ibrahim Muazzam, an ethnobotanist and staff of the
department of medicinal plant research and traditional medicine,
National Institute for Pharmaceutical Research andDevelopment
(NIPRD) and by staff of the Forestry Research Institute of Nigeria
(FRIN) in Ibadan and assignment of the correct botanical names
was done based on www.plantlist.org.
Assessment of the potential HDIs was done by analysing
the prescription drugs and herbal medicines used by the
patients against published information about any known
pharmacokinetic effects to identify possible overlapping effects
that might pose a risk.
Statistical Analyses
The descriptive and inferential statistics to determine measures
of frequency and relationship between variables were carried out
using IBM SPSS statistical package (version 22, IBM U.S.A.).
Chi square test was used to test the association of herb use with
patients’ background characteristics, such as gender, age groups,
presence of co-morbidities, and cost of monthly prescription.
A significant relationship between variables was identified if
p < 0.05.
RESULTS
Patients’ Background Characteristics and
Health Status
A total number of 112 patients with type-2 diabetes, 37 from
Central hospital Benin-city and 75 from General hospital Lagos
gave their consent and were interviewed for the study. A
summary of the background characteristics of the interviewed
patients is given in Table 1. Five age categories were created:<30
years, 31–45 years, 46–60 years, 61–75 years, and >75 years.
Most of the patients were aged between 61 and 75 years (50.9%),
followed by those between 46 and 60 years (34.8%).
More than 70% of the patients had one or more chronic co-
morbidity alongside their diabetes, the most common of which
was hypertension. The other identified co-morbidities were
arthritis, arteriosclerosis, hypercholesterolemia and neuropathy
(Table 1). Fifty percent of the patients took herbal medicines
alongside their prescription drugs either for diabetes, for one
of the co-morbidities or for the management of diabetes-
related side effects, such as erectile dysfunction. Fourteen
patients had recently discontinued their use of herbal medicines.
For those who gave reasons, three said it was “based on
Frontiers in Pharmacology | www.frontiersin.org 2 August 2016 | Volume 7 | Article 248
Ezuruike and Prieto Herb-Drug Interaction in Nigerian Diabetic Patients
TABLE 1 | Tabular summary of data from patients with type-2 diabetes.
Background characteristics #Patients (%) Use of herbal medicine (%)
Yes No
Gender Male 43 (38.4) 23 (20.5) 20 (17.9)
Female 69 (61.6) 33 (29.5) 34 (30.4)
Age groups (years) ≤30 1 (0.9) 0 (0.0) 1 (0.9)
1–45 9 (8.1) 4 (3.6) 5 (4.5)
46–60 39 (34.8) 19 (16.9) 20 (17.9)
61–75 57 (50.9)6 30 (26.8) 25 (22.3)
>75 (5.4) 3 (2.7) 3 (2.7)
Presence of co-morbidities Hypertension + Arteriosclerosis + Arthritis 1 (0.9) 0 (0.0) 1 (0.9)
Hypertension + High cholesterol + Arthritis 6 (5.4) 4 (3.6) 2 (1.8)
Hypertension + High cholesterol + Arteriosclerosis 1 (0.9) 1 (0.9) 0 (0.0)
Hypertension + High cholesterol 17 (15.2) 11 (9.8) 6 (5.4)
Hypertension + Arteriosclerosis 2 (1.8) 1 (0.9) 0 (0.0)
Hypertension + Arthritis 4 (3.6) 2 (1.8) 1 (0.9)
Hypertension + Neuropathy 2 (1.8) 1 (0.9) 1 (0.9)
Hypertension 46 (41.1) 22 (19.6) 24 (21.5)
High cholesterol 1 (0.9) 1 (0.9) 0 (0.0)
None 30 (26.8) 13 (11.6) 17 (15.2)
Monthly prescription cost (Naira)* <5000 23 (20.5) 9 (8.0) 12 (10.7)
5001–10,000 27 (24.1) 17 (15.2) 10 (9.9)
10,001–15,000 10 (8.9) 4 (3.6) 6 (5.4)
>15,000 2 (1.8) 0 (0.0) 2 (1.8)
# Information about herb use in two patients was not given.
*Data on cost of prescription was not obtained from all the interviewed patients (£1 ≈ 265 Naira, $1 ≈ 170 naira www.xe.com; Accessed 13th Nov 2014).
advice by their doctor,” two said it was “due to perceived
side effects,” and one patient was “disappointed at its lack of
efficacy.”
Relationships between Variables and
Predictors of Herbal Medicine Use
Approximately 50% of all patients used herbal medicines
alongside their prescription drugs, and this percentage was the
same for both males and females. Almost 60% of those who used
herbal medicines were older patients aged between 61 and 75
years (Table 1). This is possibly because the highest number of
patients with type-2 diabetes fell within that age group. As such,
there was no statistically significant association between age and
herb use (x2 = 1.555, df = 4, p= 0.817).
Given that the inherent characteristics of the individual (age
and sex) were not a predictor of herb use, we hypothesized that
the presence of one or more chronic co-morbidity as well as a
high monthly prescription cost could be an incentive for patients
to use herbal medicines as evidenced by the study carried out
by Nahin et al. (2012). Although there were more herb users
within the group of patients with two or more chronic co-morbid
conditions than the group with only one or none at all, this
relationship was not statistically significant (x2 = 3.041, df = 3,
p= 0.385). For themonthly cost of prescription, a higher number
of patients who spend less money for their drugs (<10,000 naira)
used herbs than those who had to pay more, but this relationship
was also not statistically significant (x2 = 4.643, df = 3, p =
0.2). Thus, the choice of herbal medicine use was independent
of the presence of co-morbidities or the monthly cost of
prescriptions.
In trying to understand the divergent relationship between
number of co-morbidities and monthly cost of prescription
with herb use, it was observed that the prescription cost was
not necessarily dependent on the number of co-morbidities the
patient was being treated for, but on the medications on the
patient’s prescription. For instance, a patient with only diabetes
may have been prescribed gliclazide by his/her doctor, which
is more expensive than other types of sulphonylureas. On the
other hand, another patient having diabetes alongside other
co-morbidities might be prescribed a cheaper sulphonylurea,
such as glibenclamide as well as other non-expensive medications
for their co-morbidities resulting in lower prescription costs.
Thus, a patient with more co-morbidities may not necessarily
have higher prescription costs. At the same time, based on
the results of the study, patients with more drugs on their
prescription due to co-morbidities or those with the need to
spend more money on their prescription drugs were not more
likely to use herbs than those without. As a result, the presence
of diabetic complications wasn’t identified as a predictor for herb
use among patients with type-2 diabetes.
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Pharmacological Management of the
Patients
A summary of the drugs used in the pharmacological
management of diabetes in the interviewed patients is given in
Table 2. Eighty percent of the patients were prescribed more
than one medication for their diabetes. This is in addition to
the drugs prescribed for other existing co-morbidities. These
results corroborate other studies that have shown inadequate
blood glucose control with monotherapy in patients with type-
2 diabetes. Thus, despite the lack of an association between the
presence of co-morbidities or number of medications and the
use of herbal medicines as expected, diabetic patients could still
be high risk candidates for HDIs since they are likely to be on a
multiple drug regimen of orally administered drugs.
Less than 10% of the patients interviewed used insulin either
singly or in combination with an oral hypoglycaemic agent
for their diabetes management. This isn’t surprising as despite
the proven efficacy of insulin in blood glucose control, its
level of compliance and/or acceptance amongst patients with
type-2 diabetes is still low due to its relatively higher cost
compared to oral hypoglycaemic drugs and unpreferred mode of
administration. Additional factors which are unique to Nigeria
and other developing countries include limited availability and
unreliable storage facilities, given that constant power supply isn’t
guaranteed. Thus, despite the decreased risk of pharmacokinetic
interactions with insulin, patients are still unlikely to use it as an
alternative.
Pharmacokinetic and Toxicological Profile
of Herbal Medicines Used by Patients
Out of the 56 patients who admitted to using herbal
medicines alongside prescription drugs for their disease
management, <40% were aware of their identity. For these
TABLE 2 | Tabular summary of the pharmacological management of the
patients’ based on their prescribed hypoglycaemic agents.
Anti-diabetic drug(s) No of patients Presence of
co-morbidities*
Glibenclamide only 1 1
Insulin only 4 2
Insulin + Gliclazide 1 0
Metformin + Acarbose + Glibenclamide 2 1
Metformin + Acarbose + Gliclazide + Insulin 1 1
Metformin + Glibenclamide 42 25
Metformin + Gliclazide 10 8
Metformin + Gliclazide + Pioglitazone 3 3
Metformin + Glimepiride 19 16
Metformin + Glimepiride + Pioglitazone 2 2
Metformin + Insulin 3 2
Metformin + Insulin + Glibenclamide 2 1
Metformin + Pioglitazone 1 1
Metformin + Vidagliptin 1 1
Metformin only 18 17
*The presence of co-morbidities indicates that there are other non-hypoglycaemic agents
on the patient’s prescription.
patients, they either grew the herbs themselves in their gardens
or they purchased them from herbal markets. The remaining
60% were unaware of the identity of the herbal medicine
used, primarily because these were unlabeled preparations
(often multi-component) given to them by herbalists, whose
constituents were not disclosed. A number of patients however
said they were not very interested in finding out the identity as
long as the preparation was effective. They considered herbal
medicines to be relatively “safe” compared to conventional
medicines. For this cohort of patients, the risk of HDIs would
be greater as they wouldn’t be able to provide any information
to their physicians/healthcare practitioners that can enable them
provide appropriate advice with regards to its efficacy and/or
safety.
Twelve medicinal plants were identified among the patients
who knew the composition of the herbal medicines which
they used for their disease management (Table 3). An extensive
review of plants used in diabetes management in Nigeria,
including information about their interactions with known
pharmacokinetic parameters had previously been carried out
by the authors (Ezuruike and Prieto, 2014); and this was used
for the literature analysis. Camellia sinensis was the only plant
mentioned by the patient which was not in the review. An
independent literature search carried out for this did not however
yield any published data on studies evaluating its possible
interaction with known pharmacokinetic parameters.
For all of the 12 identified plants, pharmacological evidence
validating their traditional use in diabetesmanagement have been
published. As shown in Table 3, eight of the identified plants
have also been shown to interact with known pharmacokinetic
parameters, with a potential to causeHDIs when co-administered
with prescription medicines. In addition, three of the plants—
Azadirachta indica A. Juss, Picralima nitida (Stapf) T. Durand
and H. Durand, and Terminalia catappa L. have been known to
cause specific organ toxicities in large doses (Table 3).
Assessment of Potential Herb-Drug
Interactions
Table 4 gives a summary of the pharmacokinetic effects of
the different drugs prescribed to the interviewed patients. In
particular, the table highlights overlapping effects with some of
the identified herbal medicines on enzymes and/or proteins that
are common targets for drug interactions. This assessment shows
that based on available information, all of the prescribed drugs
may interact with one or more of 7 out of the 12 identified herbs
(Table 4).
Concurrent use of Albemoschus esculentus (okro) with
metformin is a case to highlight, given that the potential HDI
is based on in vivo experimental evidence and because of the
extensive use of the drug by diabetic patients. Although the
experiment was carried out only with metformin, given that
AE decreases intestinal absorption, it could also affect any
other co-administered drug. Persea americana (Avocado) leaves,
Vernonia amygdalina (bitter leaf), andMangifera indica (mango)
leaves interfere with the P-glycoprotein (P-gp) eﬄux pump
and/or cytochromes 1A2 and 3A4 and could subsequently affect
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TABLE 3 | Tabular summary of the medicinal plants used by the patients and their pharmacokinetic profile.
Botanical name of
medicinal plant
(Common/Local name as
used by patient)
Number of Patients (%) Effect on intestinal P-gp or other
absorption mechanisms
Effect on cytochromes or other
hepatic enzymes (GSTs, ALT, AST)
Other toxic effects
Vernonia amygdalina Delile
(Bitter leaf/Onugbu)
13 (11.6) Inhibits P-gp efflux activity (Oga et al.,
2012)
– –
Ocimum gratissimum L.
(Scent leaf/Nchonwu)
5 (4.5) Dose dependent increase in AST and
ALT levels (Ajibade et al., 2012)
Musa paradisiaca
(Plantain/Banana)
3 (2.7) Polyvalent cations in the plant form
non-absorbable complexes with
certain drugs (Nwafor et al., 2003)
– –
Mangifera indica L.
(Mango)
3 (2.7) Inhibits the P-gp efflux activity (Chieli
et al., 2009)
Inhibits CYP 1A1/2 and 3A4 activities
in rat liver microsomes (Rodeiro et al.,
2009)
–
Persea americana Mill.
(Avocado pear)
2 (1.8) – Inhibits CYP 3A4/5/7 enzymes to
different extents (Agbonon et al.,
2010)
–
Gongronema latifolium
Benth. (Utazi)
1 (0.9) – – –
Abelmoschus esculentus
(L.) Moench (Okro)
1 (0.9) Water soluble fractions inhibits
metformin absorption in vivo (Khatun
et al., 2011)
– –
Anarcadium occidentale L.
(Cashew)
1 (0.9) – – –
Azadirachta indica A. Juss.
(Neem)
1 (0.9) – – Pharmacotoxic effects of
neem oil in lungs and CNS
(Gandhi et al., 1988)
Camellia sinensis (L.) Kuntze
(Tea)
1 (0.9) – – –
Picralima nitida (Stapf)
T. Durand and H. Durand
(Mkpokiri/Abere)
1 (0.9) – Elevated AST, ALT, and GSH levels
(Kouitcheu Mabeku et al., 2008)
Hepatotoxic effects (Fakeye
et al., 2004)
Terminalia catappa L.
(Tropical almond)
1 (0.9) – – Hepatotoxic at high doses
due to punicalagin (Lin
et al., 2001)
Unknown 36 (31.9) NA NA NA
Discontinued 14 (12.4) NA NA NA
any drugs dependent on these enzymes and/or transporter. In
addition, it can be seen from the table that mango leaves have the
potential to interact with almost all the drugs in the table, since
every drug is either metabolized by CYP 3A4 or is a substrate
for P-gp. Finally, ingestion of Ocimum gratissimum (scent) leaf,
Picralima nitida (akuamma) plant, and/or Terminalia catappa
(tropical almond) could enhance the adverse hepatic effects of
pioglitazone and atorvastatin.
With the above information, a practical assessment of
potential HDI is herein carried out for one of the interviewed
respondents “X,” a 41 year old lady who was taking the squeezed
extract of Vernonia amygdalina (VA) regularly as well as an
overnight decoction of Mangifera indica (MI) and had the
following drugs on her prescription—Metformin 1 g twice daily,
Glimepiride 4mg daily, Lisinopril 2.5mg daily, Atorvastatin
20mg daily, and Aspirin 75mg daily. A combination of the
inhibitory effects of VA and MI on P-gp eﬄux activity as
well as the ability of metformin to decrease P-gp expression
(Kim et al., 2011), could bring about an overall increase in
the plasma concentration of atorvastatin beyond the expected
level, given that atorvastatin is a known P-gp substrate.
Atorvastatin is however also dependent on CYP3A4 enzyme
activity for metabolism to its active metabolite (Lennernäs,
2003). With significant CYP3A4 inhibition by MI, the clinical
effect of atorvastatin would not be seen despite its high plasma
concentration given that the metabolite is the pharmacologically
active entity.
With this knowledge of the pharmacokinetics of her
herbal medicines as highlighted in Table 3; and based on
the information provided in Table 4, a recommendation to
discontinue the use of MI would be provided for this patient in
this case so as not to affect the therapeutic benefits of atorvastatin
given that its metabolism is absolutely essential to its effect. On
the other hand, there might not be a need to discontinue her use
of VA unless its effect on P-gp is going to result in a significant
increase in the plasma concentration of atorvastatin. For this, a
dosage adjustment may then be required particularly where clear
evidence of the medicinal plant has been shown.
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TABLE 4 | Map of the potential pharmacokinetic interaction between the prescribed drugs and the herbal medicines used by the patients.
Prescription drug Pharmacokinetic effects (Sweetman, 2011; Ezuruike and Prieto, 2014)
Intestinal absorption Efflux Cytochromes Liver toxicity
P-gp 1A2 2B6 2C8 2C9 2C19 2D6 2E1 3A4 AST/ALT
Glibenclamide a,b
VA, MI
a a
MI, PA
Metformin AE B
Pioglitazone a
MI, PA
d
OG, PN, TC
Sitagliptin a
VA, MI
Vidagliptin a
VA
Amlodipine b,c
Indapamide a
MI, PA
Losartan a a
MI, PA
Nifedipine b
MI
b a
MI, PA
Atorvastatin a,b
VA, MI
a
MI, PA
d
OG, PN,TC
Clopidogrel a a a a
MI, PA
Tramadol a a a
MI, PA
Key: For the prescription drugs, a is an identified substrate of the enzyme/protein; b inhibits enzyme/protein activity; cenhances enzyme/protein activity; d increases plasma levels of
transaminases. The two letter codes denotes a herb which also affects the same PK target of the prescription drug: MI, Mangifera indica (Mango); VA, Vernonia amygdalina (Bitter leaf);
OG, Ocimum gratissimum L. (Scent leaf); PN, Picralima nitida (Akuamma plant); AE, Abelmoschus esculentus (Okro); PA, Persea americana (Avocado pear); TC, Terminalia catappa
(Tropical almond).
DISCUSSION
The increased use of herbal medicines by patients alongside
their prescription drugs has raised concerns for HDIs, which
may be clinically relevant. By introducing a new and different
approach to the results of our field study, we have carried out
an investigation into the possible risks of pharmacokinetic HDIs
amongst patients with diabetes in Nigeria; as well as a practical
example with one patient of how such an assessment can be
carried out given available information. One of the key findings
of our study was that over 50% of diabetic patients in Nigeria
use herbal medicines alongside their conventional drugs for
their disease management, which highlights the large number of
patients at risk of HDI and the need for such assessments. More
worrying is that of this high number, more than 60% are unaware
of the identity of the herbal medicines being taken which in turn
highlights a complete ignorance of the risks of HDIs.
None of the observed variables—age, gender, cost of disease
management, and presence of co-morbidities was identified as
a predictor of herbal medicine use; and therefore could not be
used as a means of easily identifying patients at risk of HDIs.
Based on the study carried out by Nahin et al. (2012), we had
expected an association between the number of co-morbidities
(which directly relates to disease severity in the patient) and the
use of herbal medicine. The absence of this, even though our
study identified more users of herbal medicine amongst patients
with two or more co-morbidities, could therefore attribute non-
clinical factors as predictors of herb use.
Previous studies have indeed shown that the use of herbal
medicines by an individual is very closely linked to his/her
cultural health beliefs (van Andel and Westers, 2010). This
is also directly related to one’s perception about the health
benefits of herbal medicines. A patient is therefore more likely
to use herbal medicine if such practice is common in his/her
family and if he/she is convinced of its efficacy. Thus, the
sources of influence and people’s personal opinion about herbal
medicine could provide better prediction of herb use within
a population. Given that these factors are not in themselves
directly or clinically measurable, it further highlights the need for
proactive approaches from healthcare practitioners to enhance
increased communication with patients about their use of herbal
medicines. One limitation to our study was the absence of
information about non-clinical/cultural variables of the patients,
such as educational background, demography, occupation and
beliefs; as these would have enabled a better assessment of their
influence on the use of herbal medicines.
An analysis of the drugs commonly prescribed to patients with
diabetes show that most of these are substrates or modulators
of known pharmacokinetic parameters commonly implicated in
drug interactions. Studies have shown that the risk of harmful
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drug interactions increases with the number of drugs given to a
patient (Fakeye et al., 2008). Similarly, the risk of HDIs is greatly
increased for those patients taking herbal medicines who are
on more than one prescription drug (Patsalos et al., 2002). The
analysis done in Table 4 was only carried out for the drugs used
by the patients for diabetes and diabetic-related co-morbidities.
However, the complexities of potential drug interactions could
increase further when one begins to consider medications for
malaria or an antibiotic for an infection as well as multivitamins
that diabetic patients may also be taking alongside.
We recently conducted an extensive review of medicinal
plants used in diabetes management in Nigeria. One of the
findings of the study was the paucity of information on
investigations into pharmacokinetic interactions of commonly
administered herbal medicines, compared to experiments
validating its pharmacological activity (Ezuruike and Prieto,
2014). Given the high percentage of use, the complex
composition of most herbal medicines and the chronic
nature of the disease, there is a high risk of unidentified HDIs
amongst patients with diabetes. This makes a case for the need
for researchers to re-direct their focus into evaluating commonly
used medicinal plants for both their pharmacodynamic and
pharmacokinetic effects.
We have also shown how a true assessment of the risk
of HDIs can be possible with the knowledge of a patient’s
herbal medicine. Healthcare practitioners who are aware of their
patients’ use of herbal medicines and its identity can more
easily monitor them for any possible interactions using available
information, such as that presented in Tables 3, 4. In addition
to the expectation of an enhanced therapeutic effect for herbal
medicines which are being taken for the same indication as the
prescription drug (increased hypoglycaemia as in the case of
diabetes); one should also be on the lookout for any associated
pharmacokinetic interactions. Such information could result in
possible dose adjustments to accommodate the added benefit of
the herbal medicine, or a complete withdrawal if harmful. This
is even more important for HDIs involving the inhibition or
induction of cytochrome enzymes which are required for drug
conversions to the more active metabolites or the elimination
of pharmacologically active compounds. Clinically relevant drug
interactions have been identified between the anti-hypertensive
drug losartan and grapefruit juice (GFJ), because of the inhibitory
effects of GFJ on CYP 3A4 and the dependence of the former
on CYP3A4 for conversion to its active metabolite E3174
(Zaidenstein et al., 2001).
It is important to mention here that the availability of reliable
data is required to adequately determine the HDI liability of
herbal medicines. As with the case of GFJ and losartan above, this
was validated by evidence from the clinical study. However, data
obtained in vitro is very often required to plan and undertake a
robust clinical assessment. In addition, it has now been shown
that given the availability of in vitro data, physiologically based
pharmacokinetic (PBPK) modeling and simulation tools can be
used as an alternative means for the quantitative prediction of
HDIs without the need for clinical studies (Brantley et al., 2014;
Gufford et al., 2015).
Unfortunately, the high percentage of users of unidentified
herbal medicines due to non-disclosure by herbalists makes the
task of therapeutic monitoring of herbal medicines difficult, an
issue that is unlikely to be immediately tackled. This is because
traditional medicine practitioners/herbalists who prepare the
herbal preparations themselves insist that it is a “family secret”
of which a disclosure will rob them of their business (Ogbera
et al., 2010). They are therefore often rightly reticent to reveal
all the ingredients of their remedies, because of the history of
“bio-piracy” by companies seeking to patent and profit from
their knowledge without sharing benefits (Willcox and Bodeker,
2010). This non-disclosure is a limitation to the integration of
traditional medicine in conventional healthcare systems. For this
reason, patients should be advised on the importance of knowing
the identity of their herbal medicines especially as this would
enable a proper identification of those with true therapeutic
benefits.
CONCLUSION
Given the increasing prevalence of herbal medicine use
alongside prescription medicines for disease management, this
is the first time a study has been carried out specifically
looking to identify potential HDIs amongst diabetic patients
in Nigeria. We identified a high percentage (50%) of patients
who use herbal medicines, and by so doing are exposed
to a number of pharmacokinetic interactions. The lack of
clinical predictors point toward non-measurable cultural factors
influencing the use of herbal medicines by Nigerian adult diabetic
patients. The identified pharmacokinetic HDIs are therefore
highlighted here as a template for HDI assessment as well
as to facilitate a more proactive monitoring by healthcare
professionals.
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